SynOx Therapeutics Limited, a Dublin, Ireland- and Oxford, UK-based late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, raised up to $35M in Debt funding.
Hercules Capital, Inc. (NYSE: HTGC) provided the financing, which was in addition to the recent $75m Series B round.
The company intends to use the funds to further enhance its balance sheet as it executes TANGENT, a registrational Phase 3 study of emactuzumab, its CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of TGCT.
Led by CEO Ray Barlow, SynOx Therapeutics is a late-stage clinical biopharmaceutical company developing emactuzumab, a monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other CSF-1 related and macrophage driven disorders.
Commenting on the news, Ray Barlow said: “This funding will provide SynOx with additional capital to fulfil its mission of establishing emactuzumab as a best-in-class drug, to address significant unmet medical needs and greatly improve the quality of life for as many patients as possible. We are grateful for the support from Hercules, which together with the $75m we raised recently in our Series B round, puts SynOx on a strong financial footing.”
FinSMEs
30/04/2024